No apparent modulation of the anti-apoptotic Bcl-2 or Bcl-xL protein levels was observed in all prostate cancer cell lines treated with platinum drugs and/or TRAIL (Fig 2D and S3 Fig). Here, BCL2L1 is linked to prostate cancer.